Traders should monitor the upcoming earnings call for updates on cash runway, R&D spend, and clinical trial progress, which could influence sentiment given the company's small market cap ($94M).
Price Chart
Executive Summary
Cognition Therapeutics (CGTX) announced it will release Q4 and full-year 2025 financial results on March 26, 2026, followed by a conference call. The press release contains no actual financial data, only logistical details and forward-looking statements about its clinical development programs.
Key Facts
- CGTX plans to release financial results for Q4 and full year ended December 31, 2025 on March 26, 2026 before market open.
- Management will host a conference call at 8:30 a.m. ET on the same day to discuss results and provide a business update.
- No financial figures (revenue, EPS, guidance) were disclosed in this press release.
- The company is a clinical-stage biopharma firm developing zervimesine (CT1812) for neurodegenerative diseases including Alzheimer’s and DLB.
- Forward-looking statements relate to clinical trial expectations, funding, and regulatory plans — no material operational or financial results provided.
Financial Impact
No financial impact from this release; actual results to be disclosed on March 26.
Risk Factors
- High risk of dilution given clinical-stage status and reliance on external funding.
- No revenue-generating products; valuation dependent on clinical trial outcomes and future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260277 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers